66.58
+3.77(+6.00%)
Currency In USD
| Previous Close | 62.81 |
| Open | 62.87 |
| Day High | 66.69 |
| Day Low | 62.06 |
| 52-Week High | 69.48 |
| 52-Week Low | 21.72 |
| Volume | 2.16M |
| Average Volume | 2.37M |
| Market Cap | 12.68B |
| PE | -15.81 |
| EPS | -4.21 |
| Moving Average 50 Days | 55.34 |
| Moving Average 200 Days | 42.94 |
| Change | 3.77 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $2,416.7 as of November 12, 2025 at a share price of $66.58. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,546.57 as of November 12, 2025 at a share price of $66.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BridgeBio to Participate in November Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 12:30 PM GMT
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
GlobeNewswire Inc.
Nov 03, 2025 12:30 PM GMT
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered encaleret achieving both serum and urine calcium within